News

BMA explains why it gave up GP primary care monopoly

25-Jul-08

Hamish Meldrum
Allowing alternative providers into general practice was inevitable, BMA Council chairman Dr Hamish Meldrum has said.

Speaking to the BMA’s GPs-to-be conference yesterday, Dr Meldrum explained his decision to give up the GP monopoly on primary care when negotiating the new contract.

Diversity of providers was ‘something that was happening anyway’, he said.

He added that it was necessary if GPs were to have greater control of their workload. ‘If we’re able to say no, then somebody else has got to be able to say yes,’ he said.

Dr Meldrum also criticised the ‘knee-jerk negativity’ with which GPs often greet government policy.

‘Don't be put off by older, disillusioned GPs,’ he told the younger doctors.

jonn.elledge@haymarket.com

Comment below and tell us what you think

Comments

JOHN PIKE

25/07/2008

Is it any wonder that the older GPs feel disillusioned after 3 zero percent pay awards, annual unilateral changes by HMG to a contract which they agreed to in good faith, the endless bureaucracy and the daily criticism of them by HMG and the media?

Maybe younger GPs shouldn't be put off by all this; after all, British General Practice is still the envy of the world, but it would be as well if younger GPs were fully aware of how serious the situation is at present.

Only registered users may comment. Log in now or register for a free account.

Login to comment


forgotten your password?

Healthcare Republic Forums

 

Jobs

 

Job of the Week

Latest Clinical Articles

Altitude-related illness

Contributed by Dr Matthew Litchfield, GP, Nottingham and Dr James Milledge, retired consultant respi... Read more

Clinical Review - Subfertility in women

Contributed by Mr David Walker, consultant obstetrician and gynaecologist at the Royal United Hospit... Read more

Stable angina pectoris

Contributed by Dr Unni Krishnan, clinical research fellow in cardiology at the Glenfield Hospital, L... Read more

Show all clinical articles

MIMS Product News

New drug - Volibris

GSK has launched Volibris (ambrisentan) for the treatment of pulmonary arterial hypertension (WHO Cl... Read more

New drug - Thymoglobuline

Thymoglobuline is an immunosuppressant for the prophylaxis of graft rejection in renal or heart tra... Read more

New drug - Tyverb

Tyverb (lapatinib) is an oral antineoplastic agent that may provide women with an alternative option... Read more